UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020203
Receipt number R000022720
Scientific Title Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc
Date of disclosure of the study information 2015/12/15
Last modified on 2018/12/17 09:31:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc

Acronym

Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc

Scientific Title

Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc

Scientific Title:Acronym

Study of a heart failure treatment using a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc

Region

Japan


Condition

Condition

heart failure

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the improvement of symptoms and QOL with a combination drug consisting of reduced coenzyme Q10, astaxanthin, citrulline, and zinc in patients with intractable heart failure.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1.BNP
2.QOL (6-min walk test, EQ-5D)
3.LVEF by echocardiography

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

coenzyme Q10

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Outpatients with chronic heart failure (including DCM and OMI) who meet the following conditions:
(1) LVEF < 40%
(2) BNP level > 200 pg/mL
(3) Plasma coenzyme Q10 concentrations < 950 ng/mL
(4) Age >= 20 years
(5) Patients who adequately understand the objectives and details of this study, and give a written informed consent

Key exclusion criteria

(1)Patients who meet the following criteria are excluded: those who have not completely recovered from a malignancy; with severe infection; suspected of having a pulmonary disease (including COPD) on a chest radiogram; who are on dialysis; and others who are found unacceptable at the discretion of the physician
(2)Patients who have taken drugs or supplements including coenzyme Q10, astaxanthin, and citrulline within the last 2 months

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Masami Sakurada

Organization

Tokorozawa Heart Center, Medical Corporation Ouyuukai

Division name

Cardiovascular desease center

Zip code


Address

2-61-11, Kamiarai Tokorozawa Saitama 359-1142

TEL

04-2940-8611

Email

masami-saku@mh.point.ne.jp


Public contact

Name of contact person

1st name
Middle name
Last name satomi kohata

Organization

A2 Healthcare Corporation

Division name

Clinical Research Department

Zip code


Address

Sumitomo Fudosan Bldg,1-4-1,Koishikawa,Bunkyo-ku,Tokyo

TEL

03-3830-1075

Homepage URL


Email

kohata-s@a2healthcare.com


Sponsor or person

Institute

Tokorozawa Heart Center, Medical Corporation Ouyuukai

Institute

Department

Personal name



Funding Source

Organization

Your Health Care Co., Ltd

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

1)所沢ハートセンター 
2)三重ハートセンター 
3)草津ハートセンター 
4)豊橋ハートセンター
5)京都桂病院 心臓血管センター 
6)帝京大学医学部附属病院 循環器内科 
7)上尾中央総合病院 心臓血管センター


Other administrative information

Date of disclosure of the study information

2015 Year 12 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 01 Month 31 Day

Date of IRB


Anticipated trial start date

2015 Year 03 Month 01 Day

Last follow-up date

2017 Year 03 Month 31 Day

Date of closure to data entry

2017 Year 05 Month 31 Day

Date trial data considered complete

2017 Year 10 Month 30 Day

Date analysis concluded

2017 Year 11 Month 30 Day


Other

Other related information



Management information

Registered date

2015 Year 12 Month 15 Day

Last modified on

2018 Year 12 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022720


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name